BOCA RATON, FLORIDA--(Marketwire - Jan. 4, 2012) - Computer Vision Systems Laboratories Corp. (OTCBB:CVSL), announced yesterday that it has successfully fabricated its patented maneuverable guidewire. Today, the company is proud to announce that our technology has been featured on front page of MedGadget.com, a leading independent journal of the latest medical gadgets, technologies and discoveries. Medgadget is written, edited and published by a group of MDs and biomed engineers.

Chief Executive Officer Thomas DiCicco, said "Now that we have the necessary proof of design to conduct demonstrations of the guidewire for interested parties and potential strategic partners, being featured Medgadget the first day after we release the video, is testament to the fact that interest is going to grow fast. We look forward to exploring these opportunities as they arise."

CVSL will continue work to make any refinements as may be necessary once the product is put in the hands of doctors, and feedback is received. CVSL plans to aggressively seek strategic partners through licensing agreements and joint ventures to manufacture and/or distribute the guidewire.

To view the article please visit: [ http://medgadget.com/2012/01/new-guidewire-with-a-remote-controlled-flexible-tip.html ]

About the Maneuverable Guidewire

This guidewire (US Patent 7,141,024 Nov 28, 2006) is unique, easy to use, and intended for use in all PTCA procedures. The maneuverable coiled guidewire is based on the "Buckling" theory in which the tip is bent according to the force applied to it. It is made of a super elastic NiTi (nickel titanium) PTFE (Teflon) coated coil and a thin wire disposed in it. The distal end of the coil is treated in such a way that when the inner wire is pulled the distal tip buckles and bends accordingly. This feature is designed to allow the doctor to easily maneuver through the most tortuous vessels.

About Computer Vision Systems Laboratories

Computer Vision System Laboratories Corp, is currently traded on the OTCBB and OTCQB under the symbol CVSL.OB. CVSL is not generating any revenue at this time, either from the FDA 510k cleared Sentinel BreastScan or from its guidewire patent. New funding is critical to the future growth of CVSL. Once funded CVSL plans to lease the Sentinel BreastScan directly to doctors and other qualified medical professionals through a third party leasing company. CVSL will seek strategic partners in the industry with which it will promote its guidewire product. Potential partners include St. Jude Medical (STJ - NYSE), Cordis, a Johnson and Johnson company (JNJ - NYSE), Boston Scientific (BSX - NYSE), Coviden (COV - NYSE), Vascular Solutions (VASC - NASDAQ). Parties interested in discussing the guidewire or investment opportunities may contact the CEO at [ thomasdicicco@CVSLAB.com ].